Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
28 January 2023 - 08:31AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2023
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ¨
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Other Events
On January 25, 2023, AnPac Bio-Medical Science Co., Ltd. (the
“Registrant”) issued a press release announcing the entry into of
US$5.2 million of definitive investment agreements with several
third party investors. A copy of the press release issued by the
Registrant in connection therewith is furnished herewith as Exhibit
99.1.
The information in this Current Report on Form 6-K and Exhibit 99.1
attached hereto are being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act,
regardless of any general incorporation language in such
filing.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
AnPac Bio-Medical Science Co., Ltd. |
|
|
|
|
By: |
/s/Haohan
Xu |
|
|
Name: |
Haohan Xu |
|
|
Title: |
Co-Chief Executive Officer |
Dated: January 27, 2023
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2023 to Mar 2023
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2022 to Mar 2023